MTRI

InMed Pharmaceuticals Inc.

HealthcarePHARMACEUTICAL PREPARATIONS

Insider activity for last month from Oct 16 to Nov 16.

How these metrics are calculated

Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.

Total buying$34.6k1 buy
Total selling$00 sales
Net open-market+$34.6kBuying minus selling
Active insiders9Distinct reporting owners

MTRI transaction history

Newest filings · 20 transactions per page

Latest insider transactions

Form 4 filings from last month.
Newest company filings
InsiderActivityDisclosed valueFiled (ET)
Seurer Jerad G.
SR
SR
Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Large acquisition
Units acquired were at least 25% of reported post-transaction holdings.
Derivative securitySEC filing ↗
$0View disclosure →
Sandler Laura Lee
Director
DIR
Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Large acquisition
Units acquired were at least 25% of reported post-transaction holdings.
Derivative securitySEC filing ↗
$0View disclosure →
Hagen Brett R
SR
SR
Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Large acquisition
Units acquired were at least 25% of reported post-transaction holdings.
Derivative securitySEC filing ↗
$0View disclosure →
Divis Gregory J
SR
SR
Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Large acquisition
Units acquired were at least 25% of reported post-transaction holdings.
Derivative securitySEC filing ↗
$0View disclosure →
Bruno Julianne
Director
DIR
Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Large acquisition
Units acquired were at least 25% of reported post-transaction holdings.
Derivative securitySEC filing ↗
$0View disclosure →
Pernice Michelle Patricia
Director
DIR
Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Large acquisition
Units acquired were at least 25% of reported post-transaction holdings.
Derivative securitySEC filing ↗
$0View disclosure →
Shegog Todd
Director
DIR
Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Large acquisition
Units acquired were at least 25% of reported post-transaction holdings.
Derivative securitySEC filing ↗
$0View disclosure →
ADAR1 Capital Management, LLC
10% owner
10%
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
10% owner buy
The buyer is a beneficial owner of more than 10% of the company.
Large buy
A buy above $1.0M, or above twice the company’s median insider trade with at least three prior trades in the sample.
SEC filing ↗
$34.6kView disclosure →

Insider activity report

Calendar-month buckets within the selected date range

Latest filing: Nov 12, 2026

Open-market transaction mix · 1 transactions in the selected period
1 buys100%·0%0 sells

Code A includes awards, grants and other acquisitions; these are not open-market buys. A rolling period can include partial calendar months.

View exact monthly counts and disclosed values
Monthly activity within the selected period; unknown values remain unknown.
MonthBuysSellsAwards (A)Buy valueSell valueNet P/S value
Oct 2026000$0$0$0
Nov 2026107$34,571.59$0+$34,571.59

Distinct insiders active

Reporting-owner CIKs by month · peak Nov 2026 (9)
Oct 2026: 0 insidersNov 2026: 9 insiders
Oct 2026Nov 2026
9distinct insiders in selected period
Largest insider activity
By absolute net disclosed value · current transaction page
5 insiders
Filing, role and holdings details

Filing-only signals

Deterministic matches in the selected period

Recent filing activity
Most recent 6 transactions on this page · color = transaction code

Filing detail checks

Secondary metrics for the selected period
Largest buy$34.6k
Largest sale—
10b5-1 detected0
Amended rows0

Transaction codes

By Form 4 transaction code in selected period
8transactionstxns
  • A · Grants / awards · dominant7 · 88%
  • P · Open-market buys1 · 13%

Activity by reported role

A joint filing can contribute to multiple roles
Director4
SR3
10% owner1

Reported Holdings After

Separated by insider, security, and ownership type

Schneeberger DanielCommon Shares · Indirect · See Footnote
98.3k98.3kNov 5, 2026Nov 5, 2026
98,297Nov 5, 2026
Shegog ToddStock Option (Right to Buy) · Direct
37.0k37.0kNov 9, 2026Nov 9, 2026
37,000Nov 9, 2026
Bruno JulianneStock Option (Right to Buy) · Direct
37.0k37.0kNov 9, 2026Nov 9, 2026
37,000Nov 9, 2026
Divis Gregory JStock Option (Right to Buy) · Direct
1.56M1.56MNov 9, 2026Nov 9, 2026
1,560,599Nov 9, 2026
Hagen Brett RStock Option (Right to Buy) · Direct
171k171kNov 9, 2026Nov 9, 2026
171,000Nov 9, 2026
Sandler Laura LeeStock Option (Right to Buy) · Direct
37.0k37.0kNov 9, 2026Nov 9, 2026
37,000Nov 9, 2026

These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.

Filing activity heatmap
Current transaction page only · each cell is a filing date · buys green, sells red
2 active days
Oct 16 → Nov 16
LessMore

InMed Pharmaceuticals Inc. Insider Activity FAQ

SEC Form 4 context

Who recently reported transactions at InMed Pharmaceuticals Inc.?

Seurer Jerad G., Sandler Laura Lee, Hagen Brett R, Divis Gregory J, Bruno Julianne, Pernice Michelle Patricia, Shegog Todd, ADAR1 Capital Management, LLC, Schneeberger Daniel.

When was the latest reported open-market purchase?

ADAR1 Capital Management, LLC reported a buy on Nov 5, 2026 valued at $34.6k. Read the SEC filing.

When was the latest reported open-market sale?

No code-S sale is available for this period.

What is the recent purchase and sale balance?

Net open-market buying in the selected period was $34,571.59.

Where can I see the original SEC filing?

Every transaction row and latest-activity fact links to its original SEC filing.

What do these Form 4 transaction codes mean?

P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.